156 related articles for article (PubMed ID: 22814882)
1. Monitoring high-risk bladder cancer.
Schwentner C; Stenzl A; Gakis G
Curr Opin Urol; 2012 Sep; 22(5):421-6. PubMed ID: 22814882
[TBL] [Abstract][Full Text] [Related]
2. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
[TBL] [Abstract][Full Text] [Related]
4. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer.
Rodríguez Faba O; Palou J
Curr Opin Urol; 2012 Sep; 22(5):415-20. PubMed ID: 22825460
[TBL] [Abstract][Full Text] [Related]
6. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
Sylvester RJ
Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
[TBL] [Abstract][Full Text] [Related]
8. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
9. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.
Alvarez-Múgica M; Cebrian V; Fernández-Gómez JM; Fresno F; Escaf S; Sánchez-Carbayo M
J Urol; 2010 Oct; 184(4):1507-13. PubMed ID: 20723929
[TBL] [Abstract][Full Text] [Related]
10. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer.
Gakis G; Todenhöfer T; Stenzl A
Curr Opin Urol; 2011 Sep; 21(5):428-33. PubMed ID: 21730850
[TBL] [Abstract][Full Text] [Related]
12. Current status of molecular markers for prognostication and outcome in invasive bladder cancer.
Gakis G; Schwentner C; Todenhöfer T; Stenzl A
BJU Int; 2012 Jul; 110(2):233-7. PubMed ID: 22233187
[TBL] [Abstract][Full Text] [Related]
13. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis.
Ku JH; Lerner SP
Curr Opin Urol; 2012 Sep; 22(5):405-14. PubMed ID: 22842680
[TBL] [Abstract][Full Text] [Related]
14. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
[TBL] [Abstract][Full Text] [Related]
16. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
18. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
19. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
Szarvas T
Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
[TBL] [Abstract][Full Text] [Related]
20. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Gonzalez M; Portillo J; Ojea A; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Montesinos M; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA
J Urol; 2009 Nov; 182(5):2195-203. PubMed ID: 19758621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
